Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jul-Sep;39(3):244-251.
doi: 10.1590/1516-4446-2016-1993. Epub 2017 Mar 13.

Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs

Affiliations
Clinical Trial

Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs

Laura R Magni et al. Braz J Psychiatry. 2017 Jul-Sep.

Abstract

Objective:: To assess the effectiveness of a cognitive-behavioral therapy-based intervention (Superwellness Program) on weight gain compared with a treatment-as-usual (TAU) approach in patients treated with antipsychotics, and to evaluate the relationship between body mass index (BMI) variation and clinical variables.

Method:: Eighty-five patients treated with antipsychotics were allocated across two groups, experimental (n=59) and control (n=26). The Superwellness Program (experimental group) consisted of 32 twice-weekly 1-hour sessions, conducted by a psychologist and a nutritionist/nurse, concurrently with moderate food intake and moderate physical activity plans. Sociodemographic, clinical, and biological variables were collected at baseline, at the end of intervention (16 weeks), and after 6 months.

Results:: BMI change from baseline differed significantly between the experimental and control groups, with a larger decrease in the experimental group (F = 5.5, p = 0.021). Duration of illness moderated the effect of treatment on BMI (p = 0.026). No significant (p = 0.499) effect of intervention during the follow-up period was found. Interestingly, the intervention indirectly induced a significant (p = 0.024) reduction in metabolic risk by reducing BMI.

Conclusion:: A cognitive-behavioral therapy-based intervention could be useful in reducing weight in a clinical population taking antipsychotics, with consequent benefit to physical and mental health.

PubMed Disclaimer

Conflict of interest statement

The study received partial financial support from Eli Lilly. The authors report no conflicts of interest.

Figures

Figure 1
Figure 1. Structural equation model for longitudinal analysis of body mass index (BMI) changes: standardized estimates. Black dotted line depicts the covariance parameters between Global Assessment of Functioning (GAF), duration of illness, and intervention. E1-E5 indicate the measurement errors. The categorical variables gender and intervention refer to the male and Superwellness groups respectively. The number of different parameters to be estimated was 22, including covariance parameters for improving the model fit. *p < 0.05; p < 0.001.

References

    1. Attux C, Martini LC, Elkis H, Tamai S, Freirias A, Camargo Md, et al. A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. BMC Psychiatry. 2013;13:60. - PMC - PubMed
    1. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975–81. - PubMed
    1. Casey DE, Hansen TE. Excessive mortality and morbidity associated with schizophrenia. In: Meyer JM, Nasrallah HA, editors. Medical illness and schizophrenia. 2nd ed. Washington: American Psychiatric Publishing; 2009. pp. 17–36.
    1. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65:13–26. - PubMed
    1. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196:116–21. - PMC - PubMed

Substances